Entry Point Capital, LLC Vanda Pharmaceuticals Inc. Transaction History
Entry Point Capital, LLC
- $188 Million
- Q2 2025
A detailed history of Entry Point Capital, LLC transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 17,520 shares of VNDA stock, worth $75,686. This represents 0.04% of its overall portfolio holdings.
Number of Shares
17,520Holding current value
$75,686% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding VNDA
# of Institutions
151Shares Held
45.3MCall Options Held
20KPut Options Held
999K-
Black Rock Inc. New York, NY8.14MShares$35.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.57MShares$15.4 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.45MShares$14.9 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.12MShares$13.5 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.59MShares$11.2 Million0.0% of portfolio
About Vanda Pharmaceuticals Inc.
- Ticker VNDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,561,500
- Market Cap $244M
- Description
- Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...